⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 14, 2026Science Translational Medicine

Rifampicin-resistant TB: An inflection point in antimicrobial resistance

Cesar Augusto Roque‐Borda João Perdigão Fernando R. Pavan

View at Publisher

Ask AI

Bookmark

Share

Abstract

Rifampicin-resistant TB should be integrated into the global AMR response through diagnostics, surveillance, and optimized treatment regimens.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roque‐Borda et al. (2026) studied this question.

synapsesocial.com/papers/6ad1beba6b989d2d588143d0 https://doi.org/10.1126/scitranslmed.aeg5988

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Diagnosis and Treatment of Multidrug/Rifampicin-Resistant Tuberculosis2025
2<i>In vitro</i> antimicrobial resistance properties of rifapentine and rifampicin are indistinguishableClinical Trial · 2026
3Identification of gene targets that potentiate the action of rifampicin on Mycobacterium bovis BCG2024
4Rifampicin Resistance Pattern of Mycobacterium tuberculosis Infection in Tertiary Care Hospital Settings2024 · 4 citations
5A Study on Rifampicin Resistant Mycobacterium Tuberculosis in a Tertiary Care Hospital Setting in Mysuru, India2024

More related papers

Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates: an in-vitro longitudinal study2024
Low rifampicin and early signs of next-line drug resistances: findings from Madagascar’s 2023–24 nationwide drug resistance survey2026
Missed rifampicin and isoniazid resistance by commercial molecular assays2024

More from Science Translational Medicine

Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s diseaseWed,
Prevention is better than cureWed,